New possibilities for combination therapy of sleep disorders discussed at the symposium held with the support of NovaMedica as part of the First Russian Neurological Congress

An interesting discussion of new possibilities and prospects in the treatment of insomnia took place at the symposium Combination Therapy of Sleep Disorders: Possibilities and Prospects organized with the support of NovaMedica within the framework of the First Russian Neurological Congress in Moscow. The urgent nature of this topic was evident – the hall was full! Participants – more than 100 representatives of the medical community – noted the valuable opportunity to gain fresh knowledge first-hand in a comprehensive manner from well-known specialists in somnology, neurology, psychiatry and clinical pharmacology. Among other things, NovaMedica’s new drug Levroso^® Long for the treatment of sleep disorders received high praise at the symposium.

President of the Russian Society of Somnologists Mikhail POLUEKTOV (Doctor of Medical Sciences, Associate Professor of the Department of Nervous System Diseases and Neurosurgery of the Sechenov First Moscow State Medical University) spoke in his report about the neurobiology of insomnia and the psychobiosocial approach to its research and treatment.

Head of the Department of Psychiatry, Psychotherapy and Psychosomatic Pathology at the Faculty of Continuing Medical Education of the Patrice Lumumba Peoples’ Friendship University of Russia Vladimir MEDVEDEV (Associate Professor, Doctor of Medical Sciences) in his lecture on “Anxiety and sleep: cerebral mechanisms of interrelation and practical recommendations” provided information about the results of studies on the effectiveness of Levroso^® Long. He noted, in particular, that the data show an enhancement in sleep quality, as well as significant improvement in the patient’s condition upon and after awakening.

Experts mentioned the pharmacotherapeutic effectiveness of the combination of two active ingredients, prolonged melatonin and diphenhydramine, in Levroso^® Long.

Elena CHUKANOVA, Doctor of Medical Sciences, Professor of the Department of Neurology and Neurosurgery of the Faculty of Medicine of the Pirogov Russian National Research Medical University, said in her speech:

“The action of the drug mimics the physiological release of melatonin, with peak concentrations reached approximately in one and a half to two hours after administration. The addition of diphenhydramine speeds up the process of falling asleep. The advantage of the drug, this combination, ensures quick falling asleep and high-quality sleeping, and, unlike many sleep-inducing drugs, it is not addictive, which is extremely important for us.” 

Marina ZHURAVLEVA (Doctor of Medical Sciences), Deputy Director of the Center for Clinical Pharmacology of the Scientific Center for Expert Evaluation of Medicinal Products of the Russian Ministry of Health, Professor of the Department of Clinical Pharmacology and Propedeutics to Internal Diseases of the Sechenov First Moscow State Medical University, spoke about additional possibilities for pharmacotherapy of insomnia through suppression of wakefulness centers and influence on the biological clock.

The high interest in the topic of sleep disorder therapy was evidenced by the lively discussion after the official part and on the sidelines. Participants said that the opportunity to receive up-to-date information about insomnia treatment and to see the problem from different perspectives of various practitioners was very important. In their opinion, it allowed them to highlight the most significant aspects to ensure successful treatment of their patients.

Russian Neurological Congress is one of the largest federal events for the medical community. This is why NovaMedica employees, in addition to the discussion platforms, also actively worked at the stand. We value such face-to-face contact with doctors and the opportunity to directly discuss their expectations from our products and think together about how to help Russian patients more efficiently.